NEW YORK, NY / ACCESS Newswire / March 23, 2026 / The global wellness economy is valued at $6.3 trillion and is projected to reach $9 trillion by 2028. Yet, most companies continue competing in ...
Zacks Small Cap Research on MSN
INAB: Introducing INB-600, A γδ T Cell Engager Platform
Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc. (NASDAQ:INAB) reported 2024 financial ...
IN8bio announces INB-619, a novel γδ T cell therapy platform targeting CD19, showing promise in B cell depletion with reduced side effects. IN8bio, Inc. has announced the launch of its innovative γδ T ...
INB.bio Launches 2026 Growth Strategy With New Market Entries Across Africa, MENA and Southeast Asia
The MarketWatch News Department was not involved in the creation of this content. BERLIN, March 22, 2026 (GLOBE NEWSWIRE) -- Global demand for wellness products is climbing steadily, with the industry ...
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp ...
INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc (INAB). (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming ...
Indústrias Nucleares do Brasil has signed a contract with Amazônia Azul Technologias de Defesa SA (Amazul) to provide engineering services for the second phase of the uranium enrichment plant at INB's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results